Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

By LabMedica International staff writers
Posted on 30 Jun 2025

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies. More...

The standard treatment relies on chemotherapy, typically administered before surgery as neoadjuvant chemotherapy (NACT), with the aim of reducing or controlling tumor growth. However, many patients develop resistance to specific NACT regimens, which leads to poor prognoses. Due to the absence of viable alternatives, both responders and non-responders often continue receiving available chemotherapies without knowing if they will be effective. Even for those who initially respond, the chosen chemotherapy may not fully halt tumor progression or prevent metastasis, and it frequently causes harmful side effects. A major unmet clinical need is the development of a personalized, patient-specific precision oncology tool capable of accurately forecasting individual responses to different NACTs in a timely manner.

Previously, scientists developed “organoids” from biopsied EAC cells—3D miniature esophageal tissues formed from tissue-specific stem cells that replicate essential characteristics of the esophageal epithelial lining. Yet, these organoids lack vital elements of the tumor microenvironment (TME), such as stromal fibroblasts and collagen structures, and therefore do not accurately mimic how real tumors respond to NACT. Now, a new collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University (Boston, MA, USA) and McGill University Health Centre (Montreal, Canada) has led to a promising personalized medicine solution aimed at improving chemotherapy outcomes for EAC patients. The team utilized the Wyss Institute’s human Organ Chip microfluidic culture technology to co-culture patient-derived EAC organoids alongside stromal cells collected from the same biopsies, which were obtained by the McGill team as part of a clinical cohort study. This approach resulted in patient-specific Cancer Chip models that include essential components of the TME.

By reconstructing key aspects of the TME in vitro, the researchers significantly enhanced the accuracy of predicting how a patient’s tumor would respond to standard NACT, outperforming the traditional, simpler 3D organoid models. The method delivers results within 12 days from model initiation, allowing for the timely stratification of EAC patients into likely responders and non-responders. It also supports the testing of alternative NACTs using different chemotherapeutic agents for patients showing resistance—all within a clinically actionable timeframe. These findings have been published in the Journal of Translational Medicine.

“This patient-centered approach strongly builds on our previous successes using human Organ Chip technology to recapitulate each individual cancer patient's TME outside their body so that we can identify the drug combination that will work best for that very patient. This new way to approach personalized medicine could be implemented at clinical centers focusing on the care of patients suffering from many different types of cancer, such as the one run by our collaborators with patients who have esophageal cancer,” said Donald Ingber, M.D., Ph.D., Founding Director at the Wyss Institute, who led the research. “Perhaps equally important, it can also be used as a pre-clinical testbed to break new ground in the development of tumor- or stroma-targeted therapies for cancer patients and enable the discovery of biomarkers that could be used to monitor and optimize drug effects in these patients."

Related Links:
Wyss Institute
McGill University Health Centre


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.